Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of hard-to-treat disease in a unique and transformative approach to drug discovery and development.
Alchemab takes an unbiased and function-first approach using three complementary processes and cutting-edge technologies to identify naturally protective antibodies.
Alchemab’s engine is enabled through collaborations with patient representative groups and biobanks around the world with whom we partner to further our understanding of disease.
Alchemab takes an unbiased and function-first approach using three complementary processes and cutting-edge technologies to identify naturally protective antibodies.
Alchemab’s engine is enabled through collaborations with patient representative groups and biobanks around the world with whom we partner to further our understanding of disease.
Location: United Kingdom
Employees: 11-50
Total raised: $148.59M
Founded date: 2019
Founders name: Uri Laserson
Founders Related Locations: United States, New York, New York
Investors 7
| Date | Name | Website |
| - | DCVC | dcvc.com/ |
| - | Camford Ca... | camford.co... |
| - | RA Capital... | racap.com |
| 22.04.2021 | Lightstone... | lightstone... |
| - | DHVC | dh.vc |
| - | SV Health ... | svhealthin... |
| 01.10.2025 | Ono Ventur... | onoventure... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 10.07.2026 | Series A | $34M | - |
| 09.09.2025 | - | $32M | Eli Lilly ... |
| 15.04.2021 | Series A | $82.59M | - |
Persons 1
| Date | First Name | Last Name | Title | |||
| - | Uri | Laserson | Scientific... | linkedin.c... | - | - |
Mentions in press and media 21
| Date | Title | Description |
| 13.07.2026 | European tech weekly recap: More than 70 tech funding deals worth over €2.8B | Last week, we tracked more than 70 tech funding deals worth over €2.8 billion and over 5 exits, M&A transactions, rumours, and related news stories across Europe. 📊 The top three industries that raised the most were clouds (€790.8 milli... |
| 11.07.2026 | Alchemab Secures £25M Series A Extension, Fuels AI-Driven Antibody Pipeline | Alchemab Therapeutics landed a substantial £25M Series A extension. The British Business Bank led this pivotal investment. It pushes Alchemab's total Series A funding to an impressive £109M. This capital injection accelerates the Cambridge,... |
| 10.07.2026 | Digantara Industries Raises USD50M in Series B Funding | Digantara Industries, a Bengaluru, India-based company which specializes in space surveillance and intelligence, raised USD50M in Series B funding. Backers included 360 ONE Asset, SBI Investments Co Japan, Ronnie Screwvala, Peak XV Partners... |
| 10.07.2026 | Alchemab Therapeutics Extends Series A Financing with USD34M | Alchemab Therapeutics, a Cambridge, UK-based clinical-stage biotechnology company, raised £25M (USD$34M) in Series A extension funding from British Business Bank. Current investors included SV Health Investors and the Dementia Discovery Fun... |
| 09.07.2026 | Alchemab Raises £25 Million Extension to Series A to Advance AI-Driven Antibody Pipeline | Clinical-stage biotechnology company Alchemab Therapeutics announced a £25 million (approximately $34 million) extension to its Series A financing from the British Business Bank. The investment marks the largest life sciences investment mad... |
| 09.07.2026 | Alchemab Therapeutics announce biggest ever life sciences investment from British Business Bank to advance its AI-enabled clinical pipeline of next generation human-derived antibodies | CAMBRIDGE, UK – Clinical-stage biotech Alchemab Therapeutics has extended its series A financing with a £25 million (USD $34m) investment from the British Business Bank – the Bank’s largest investment in a life sciences company to date. The... |
| 03.10.2025 | Ono Venture Investment invests in Alchemab. (Alchemab Therapeutics initiates Phase 1 clinical trial of ATLX-1282 and announces Series A financing extension) | - |
| 09.09.2025 | Alchemab Therapeutics initiates Phase 1 clinical trial of ATLX-1282 and announces Series A financing extension | Cambridge, UK, 9 September 2025 – Alchemab Therapeutics (Alchemab), a biopharmaceutical company which identifies and develops naturally occurring therapeutic antibodies from resilient individuals, today announced initiation of a Phase 1 fir... |
| 09.09.2025 | Alchemab Therapeutics Raises Series A Extension Financing | Alchemab Therapeutics, a London, UK-based biopharmaceutical company which identifies and develops naturally occurring therapeutic antibodies from resilient individuals, raised an undisclosed amount in Series A extension funding. Backers inc... |
| 08.03.2024 | On International Women's Day SV Venture Partner Ruth McKernan reflects on some achievements of SV biotech portfolio companies | On International Women’s Day it is extremely pleasing to note the vast majority of SV Health Investor’s biotech portfolio companies with women in their C-suite, many being led by female CEOs. It is one of the many reasons I was drawn to wor... |
Show more